keyword
MENU ▼
Read by QxMD icon Read
search

pneumococcal conjugate vaccine

keyword
https://www.readbyqxmd.com/read/27919900/n-acetyl-l-cysteine-and-cysteamine-new-strategies-against-mixed-biofilms-of-non-encapsulated-streptococcus-pneumoniae-and-non-typeable-haemophilus-influenzae
#1
Mirian Domenech, Ernesto García
Acute otitis media, a polymicrobial disease of the middle ear cavity of children, is a significant public health problem worldwide. It is most frequently caused by encapsulated Streptococcus pneumoniae and non-typeable Haemophilus influenzae, although the widespread use of pneumococcal conjugate vaccines is apparently producing an increase in carriage of non-encapsulated S. pneumoniae Frequently, pneumococci and H. influenzae live together in the human nasopharynx forming a self-produced biofilm. Biofilms represent a global medical challenge since the inherent antibiotic resistance of their producers demands the use of high doses of antibiotics over prolonged periods...
December 5, 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27919632/immunogenicity-and-safety-of-a-13-valent-pneumococcal-conjugate-vaccine-and-an-mf59-adjuvanted-influenza-vaccine-after-concomitant-vaccination-in-%C3%A2-60-year-old-adults
#2
Joon Young Song, Hee Jin Cheong, Hak Jun Hyun, Yu Bin Seo, Jacob Lee, Seong-Heon Wie, Min Joo Choi, Won Suk Choi, Ji Yun Noh, Jae Won Yun, Jin Gu Yun, Woo Joo Kim
BACKGROUND: Concomitant administration of influenza and pneumococcal vaccines could be an efficient strategy to increase vaccine uptake among older adults. Nevertheless, immune interference and safety issues have been a concern when more than one vaccines are administered at the same time. METHODS: Subjects aged ⩾60years were randomized in a 1:1:1 ratio to receive MF59-adjuvanted trivalent inactivated influenza vaccine (MF59-aTIV)+13-valent pneumococcal conjugate vaccine (PCV13) (Group 1), PCV13 alone (Group 2), or MF59-aTIV alone (Group 3)...
December 2, 2016: Vaccine
https://www.readbyqxmd.com/read/27918383/etiology-of-acute-otitis-media-in-children-less-than-5-years-of-age-a-pooled-analysis-of-10-similarly-designed-observational-studies
#3
Melissa K Van Dyke, Jean-Yves Pirçon, Robert Cohen, Shabir A Madhi, Andrés Rosenblüt, Mercedes Macias Parra, Khalid Al-Mazrou, Gerhard Grevers, Pio Lopez, Laura Naranjo, Felix Pumarola, Nuntigar Sonsuwan, William P Hausdorff
BACKGROUND: Acute otitis media (AOM) is an important cause of childhood morbidity and antibiotic prescriptions. However, the relative importance of the well-known otopathogens, Streptococcus pneumoniae (Spn) and Haemophilus influenzae (Hflu), remains unclear due to a limited number of tympanocentesis-based studies that vary significantly in populations sampled, case definitions, and heptavalent pneumococcal conjugate vaccine (PCV7-CRM) use. METHODS: We conducted a pooled analysis of results from ten AOM etiology studies of similar design the protocols of which were derived from a common protocol and conducted in children 3 months to 5 years of age in different countries...
November 30, 2016: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/27917323/development-and-evaluation-of-a-novel-vaccine-against-prevalent-invasive-multi-drug-resistant-strains-of-streptococcus-pneumoniae
#4
Rehab H Bahy, Hayam M Hamouda, Amal S Shahat, Aymen S Yassin, Magdy A Amin
Streptococcus pneumoniae is a pathogen that causes serious invasive infections, such as septicemia, meningitis and pneumonia in addition to mild upper respiratory tract infections. Protection from pneumococcal diseases is thought to be mediated mainly by serotype-specific antibodies to capsular antigens. Pneumococcal conjugate vaccine consists of sugars (polysaccharides) from the capsule of the bacterium S. pneumoniae that are conjugated to a carrier protein. Three pneumococcal conjugated vaccines, each directed against a group of serotypes, are registered in Egypt; however, local vaccine production is required to cover the most prevalent serotypes...
2016: PeerJ
https://www.readbyqxmd.com/read/27905836/invasive-pneumococcal-disease-from-a-tertiary-care-hospital-in-the-post-vaccine-era
#5
Sevgen Tanır Basaranoglu, Eda Karadag Oncel, Kubra Aykac, Yasemin Ozsurekci, Ali Bulent Cengiz, Ates Kara, Mehmet Ceyhan
A breakthrough infection occurring with 13-valent pneumococcal conjugate vaccine (PCV13) in Turkey are previously described. A breakthrough infection is defined as IPD in a child who had received ≥1 PCV-7 or PCV-13 and for which the pneumococcal isolate was a vaccine serotype. During one year period, among six patients with invasive pneumococcal infection, two patients were considered to have a vaccine failure with serotype 19F. Antibiotic resistance results were remarkable; macrolide resistance were observed in all strains except one, and high and intermediate penicillin resistance were determined in two strains...
December 1, 2016: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/27903558/cost-effectiveness-analysis-of-routine-pneumococcal-vaccination-in-the-uk-a-comparison-of-the-phid-cv-vaccine-and-the-pcv-13-vaccine-using-a-markov-model
#6
Emmanuelle Delgleize, Oscar Leeuwenkamp, Eleni Theodorou, Nicolas Van de Velde
OBJECTIVES: In 2010, the 13-valent pneumococcal conjugate vaccine (PCV-13) replaced the 7-valent vaccine (introduced in 2006) for vaccination against invasive pneumococcal diseases (IPDs), pneumonia and acute otitis media (AOM) in the UK. Using recent evidence on the impact of PCVs and epidemiological changes in the UK, we performed a cost-effectiveness analysis (CEA) to compare the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with PCV-13 in the ongoing national vaccination programme...
November 30, 2016: BMJ Open
https://www.readbyqxmd.com/read/27902652/circulating-antibody-1-and-2-years-after-vaccination-with-the-13-valent-pneumococcal-conjugate-vaccine-in-preterm-compared-with-term-infants
#7
Federico Martinón-Torres, Jacek Wysocki, Kimberly J Center, Hanna Czajka, Ewa Majda-Stanislawska, Felix Omeñaca, Ana Concheiro-Guisan, Francisco Gimenez-Sanchez, Leszek Szenborn, Daniel Blázquez-Gamero, Laura Moreno-Galarraga, Peter C Giardina, Gang Sun, William C Gruber, Daniel A Scott, Alejandra Gurtman
BACKGROUND: Premature infants have lower short-term immune responses to vaccination than term infants, but patterns of antibody persistence in preterm infants over longer periods are not well established. This study assessed the persistence of antibody response to the 13-valent pneumococcal conjugate vaccine (PCV13) in formerly preterm versus term infants. METHODS: In total, 100 preterm and 100 term infants received PCV13 with routine vaccines at ages 2, 3, 4, and 12 months...
November 28, 2016: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/27899227/challenges-to-estimating-vaccine-impact-using-hospitalization-data
#8
Cynthia Schuck-Paim, Robert J Taylor, Lone Simonsen, Roger Lustig, Esra Kürüm, Christian A W Bruhn, Daniel M Weinberger
Because the real-world impact of new vaccines cannot be known before they are implemented in national programs, post-implementation studies at the population level are critical. Studies based on analysis of hospitalization rates of vaccine-preventable outcomes are typically used for this purpose. However, estimates of vaccine impact based on hospitalization data are particularly prone to confounding, as hospitalization rates are tightly linked to changes in the quality, access and use of the healthcare system, which often occur simultaneously with introduction of new vaccines...
November 26, 2016: Vaccine
https://www.readbyqxmd.com/read/27895845/a-trial-of-a-7-valent-pneumococcal-conjugate-vaccine-in-hiv-infected-adults
#9
Neil French, Stephen B Gordon, Thandie Mwalukomo, Sarah A White, Gershom Mwafulirwa, Herbert Longwe, Martin Mwaiponya, Eduard E Zijlstra, Malcolm E Molyneux, Charles F Gilks
BACKGROUND: Streptococcus pneumoniae is a leading and serious coinfection in adults with human immunodeficiency virus (HIV) infection, particularly in Africa. Prevention of this disease by vaccination with the current 23-valent polysaccharide vaccine is suboptimal. Protein conjugate vaccines offer a further option for protection, but data on their clinical efficacy in adults are needed. METHODS: In this double-blind, randomized, placebo-controlled clinical efficacy trial, we studied the efficacy of a 7-valent conjugate pneumococcal vaccine in predominantly HIV-infected Malawian adolescents and adults who had recovered from documented invasive pneumococcal disease...
September 2016: Malawi Medical Journal: the Journal of Medical Association of Malawi
https://www.readbyqxmd.com/read/27889249/analysis-of-streptococcus-pneumoniae-and-haemophilus-influenzae-isolated-from-middle-ear-fluid-before-and-after-the-introduction-of-government-subsidies-for-pneumococcal-and-h-%C3%A2-influenzae-type-b-vaccines-in-japan
#10
Tadashi Hoshino, Noriko Takeuchi, Chie Fukasawa, Shoko Hirose, Hideyuki Okui, Hiroko Sato, Mari Sato, Yukiko Arimoto, Atsuko Nakano, Naruhiko Ishiwada
This study aimed to identify trends in frequency, serotype, and antimicrobial susceptibility of Streptococcus pneumoniae and Haemophilus influenzae isolated from middle ear fluid specimens of children aged≤15 years (mean, 2 years), before and after the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) and the H. influenzae type b vaccine, at a pediatric facility in Japan. Sixty-six S. pneumoniae and 88 H. influenzae strains were isolated from 820 middle ear fluid samples. Serotyping and antimicrobial susceptibility testing were performed...
November 23, 2016: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy
https://www.readbyqxmd.com/read/27885442/patterns-and-trends-of-pediatric-bloodstream-infections-a-7-year-surveillance-study
#11
N Buetti, A Atkinson, L Kottanattu, J Bielicki, J Marschall, A Kronenberg
We characterize the epidemiology of pediatric bloodstream infections (BSIs) in Switzerland. We analyzed pathogen distribution and resistance patterns in monomicrobial and polymicrobial BSIs in children from 2008 to 2014 using data from the Swiss antibiotic resistance centre (ANRESIS). A confirmatory statistical analysis was performed comparing pathogens and resistance across 20 acute care hospitals. We identified 3,067 bacteremia episodes, of which 1,823 (59 %) were considered true BSI episodes. Overall, S...
November 24, 2016: European Journal of Clinical Microbiology & Infectious Diseases
https://www.readbyqxmd.com/read/27879558/impact-of-pneumococcal-conjugate-vaccines-on-selected-head-and-neck-infections-in-hospitalized-israeli-children
#12
Tal Marom, Shiran Bookstein Peretz, Orna Schwartz, Abraham Goldfarb, Yahav Oron, Sharon Ovnat Tamir
INTRODUCTION: Streptococcus pneumoniae is a major pathogen of pediatric head and neck infections (HNIs), e.g. acute otitis media (AOM), acute mastoiditis (AM), acute bacterial sinusitis (ABS) and meningitis. The aim of the study was to characterize the epidemiology of pneumococcal HNIs (pHNIs) before, during, and after the introduction of pneumococcal conjugate vaccines (PCVs). METHODS: Children 0-16 years who were hospitalized with HNIs in the Pediatrics Department in a general hospital between 1/1/2007-12/31/2014 were retrospectively identified...
November 22, 2016: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/27869440/immunology-update-new-vaccines
#13
S Paul Starr
A new 9-valent human papillomavirus (HPV) vaccine is effective against more cancer-causing HPV types than previous vaccines. HPV vaccine series started with previous vaccines can be completed with the 9-valent vaccine. Two new influenza vaccines are available for adults 65 years and older: a high-dose vaccine and an enhanced adjuvant vaccine. These elicit stronger antibody responses than standard-dose vaccines. Current guidelines specify no preference for the new versus standard-dose vaccines. Two new group B meningococcal vaccines are intended for use during outbreaks and for patients with asplenia, complement deficiencies, frequent occupational meningococcus exposure, or for patients who desire protection from type B meningococcus...
November 2016: FP Essentials
https://www.readbyqxmd.com/read/27862712/invasive-pneumococcal-infections-in-children-following-transplantation-in-the-pneumococcal-conjugate-vaccine-era
#14
Liset Olarte, Philana Ling Lin, William J Barson, Jose R Romero, Tina Q Tan, Laurence B Givner, Jill A Hoffman, John S Bradley, Kristina G Hultén, Edward O Mason, Sheldon L Kaplan
BACKGROUND: Pediatric recipients of hematopoietic stem cell and solid organ transplants are at increased risk of invasive pneumococcal infections (IPI). Data on IPI in this population is scarce. To our knowledge, this is the first study describing the epidemiology of IPI among pediatric transplant recipients in the pneumococcal conjugate vaccine (PCV) era. METHODS: We identified transplant recipients with IPI at 8 children's hospitals in the U.S. from our surveillance database (2000-2014)...
November 9, 2016: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/27862309/study-of-greek-children-and-youths-with-cystic-fibrosis-identifies-immunisation-gaps-and-delays
#15
Helena C Maltezou, Stavros Doudounakis, Maria Lekaditi, Kalliopi Tanou, Panos Katerelos, Maria Theodoridou
AIM: Data about immunisation rates in cystic fibrosis (CF) patients are scarce. We estimated the rates and timeliness of immunisations in CF patients aged 0.55-22 years. METHODS: We studied 122 subjects at a hospital in Greece in 2014. A standard questionnaire was used to collect data and parents' opinions about immunisations. RESULTS: The complete immunisation rates were 92.6% for diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis-Haemophilus influenzae (DTaP-IPV-Hib), 96...
November 10, 2016: Acta Paediatrica
https://www.readbyqxmd.com/read/27855146/global-routine-vaccination-coverage-2015
#16
Rebecca M Casey, Laure Dumolard, M Carolina Danovaro-Holliday, Marta Gacic-Dobo, Mamadou S Diallo, Lee M Hampton, Aaron S Wallace
In 1974, the World Health Organization (WHO) established the Expanded Program on Immunization* to provide protection against six vaccine-preventable diseases through routine infant immunization (1). Based on 2015 WHO and United Nations Children's Fund (UNICEF) estimates, global coverage with the third dose of diphtheria-tetanus-pertussis vaccine (DTP3), the first dose of measles-containing vaccine (MCV1) and the third dose of polio vaccine (Pol3) has remained stable (84%-86%) since 2010. From 2014 to 2015, estimated global coverage with the second MCV dose (MCV2) increased from 39% to 43% by the end of the second year of life and from 58% to 61% when older age groups were included...
November 18, 2016: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/27847374/multiplex-urinary-antigen-detection-for-13-streptococcus-pneumoniae-serotypes-improves-diagnosis-of-pneumococcal-pneumonia-in-south-african-hiv-infected-adults
#17
Werner C Albrich, Michael W Pride, Shabir A Madhi, Jan Callahan, Peter V Adrian, Roger French, Nadia van Niekerk, Shite Sebastian, Victor Souza, Jean-Noel Telles, Glaucia Paranhos-Baccalà, Kathrin U Jansen, Keith P Klugman
BACKGROUND: A serotype-specific urinary antigen detection assay (UAD) for 13 serotypes included in the pneumococcal conjugate vaccine (PCV13) was recently reported as a useful diagnostic tool for pneumococcal pneumonia. We aimed to assess the diagnostic accuracy of the UAD in HIV-infected South African adults. METHODS: Urine specimens from a well-defined cohort of HIV-infected South African adults with pneumonia were evaluated retrospectively in the UAD assay. Pneumonia was considered pneumococcal if either sputum Gram stain, sputum culture, blood culture or immunochromatographic (ICT) BinaxNow® S...
November 9, 2016: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/27846277/pneumococcal-conjugated-vaccine-reduces-the-high-mortality-for-community-acquired-pneumonia-in-the-elderly-an-italian-regional-experience
#18
Vincenzo Baldo, Silvia Cocchio, Tolinda Gallo, Patrizia Furlan, Pierantonio Romor, Chiara Bertoncello, Alessandra Buja, Tatjana Baldovin
BACKGROUND: Community-acquired pneumonia (CAP) is an important cause of illness and death worldwide, particularly among the elderly. Previous studies on the factors associated with mortality in patients hospitalized for CAP revealed a direct association between the type of microorganism involved, the characteristics of the patient and mortality. Vaccination status against pneumococcal disease was not considered. We conducted a retrospective analysis on the mortality rates after a first hospitalization for CAP in north-east Italy with a view to examining especially the role of anti-pneumococcal vaccination as a factor associated with pneumonia-related mortality at one year...
2016: PloS One
https://www.readbyqxmd.com/read/27844262/changes-in-the-pneumococcal-disease-related-hospitalisations-in-spain-after-the-replacement-of-7-valent-by-13-valent-conjugate-vaccine
#19
L Georgalis, A Mozalevskis, M V Martínez de Aragón, M Garrido-Estepa
In Spain, anti-pneumococcal vaccination is recommended for all children under 2 years old, high-risk groups and adults ≥65 years old. However, it is not funded in most autonomous communities. This study aims to compare pneumococcal disease hospitalisation rates between Period 1 (2007-2009), when 7-valent (PCV7) vaccine was available, and Period 2 (2011-2013), after the change to 13-valent (PCV13) vaccine in Spain. Data on hospitalisations were obtained from the National Registry of Hospitalisations. We calculated hospitalisation rates (HRs) and hospitalisation rate ratios (HRRs) among periods by age group and autonomous community, for all and by clinical presentation...
November 14, 2016: European Journal of Clinical Microbiology & Infectious Diseases
https://www.readbyqxmd.com/read/27836437/post-licensure-surveillance-of-13-valent-pneumococcal-conjugate-vaccine-pcv13-in-adults-aged-%C3%A2-19years-old-in-the-united-states-vaccine-adverse-event-reporting-system-vaers-june-1-2012-december-31-2015
#20
Penina Haber, Jorge Arana, Tamara Pilishvili, Paige Lewis, Pedro L Moro, Maria Cano
BACKGROUND: The 13-valent pneumococcal conjugate vaccine (PCV13) was first recommended for use in adults aged ⩾19years with immunocompromising conditions in June 2012. On August 2014, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of PCV13 among adults aged ⩾65years. METHODS: We assessed adverse events (AEs) reports following PCV13 in adults aged ⩾19years reported to the Vaccine Adverse Event Reporting System (VAERS) from June 2012 to December 2015...
December 7, 2016: Vaccine
keyword
keyword
112012
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"